Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
ADAG
#3090
Adagene Inc. American Depositary Shares
2.9
6
-7.21%
Secteur:
Base:
Devise de Profit:
Range quotidien
Range Annuel
Changement quotidien
-7.21%
Changement Mensuel
+24.37%
Evolution sur 6 mois
+37.67%
Changement Annuel
+42.31%
Clôture Précédente
3.1
9
Open
2.9
6
Bid
Ask
Low
2.9
6
High
2.9
6
Volume
1
Marchés
Actions des Marchés US
Soins de Santé
ADAG
Open full chart
Financials
Overview
Relevé
Statistics
Dividends
Quarterly
Annual
Value
Q4, 24
TTM
Key stats
Total common shares outstanding
58.89 M
222.69 M
Valuation ratios
Enterprise value
37.28 M
275.25 M
Price to earnings ratio
-3.37
-15.36
Price to sales ratio
—
—
Price to cash flow ratio
-3.77
-18.25
Price to book ratio
2.22
7.14
Enterprise value to EBITDA ratio
—
—
Profitability ratios
Return on assets %
-0.01
0.07
Return on equity %
-0.01
0.11
Return on invested capital %
—
—
Gross margin %
—
—
Operating margin %
—
—
EBITDA margin %
—
—
Net margin %
—
—
Liquidity ratios
Quick ratio
—
—
Current ratio
2.3
14.85
Inventory turnover
—
—
Asset turnover
—
—
Solvency ratios
Debt to assets ratio
0.06
0.41
Debt to equity ratio
0.1
0.7
Long term debt to total assets ratio
0
0.23
Long term debt to total equity ratio
0.01
0.39
Per share metrics
Operating cash flow per share
-0.01
0.27
EBIT per share
—
—
EBITDA per share
—
—
Total debt per share
0.09
1
Cash per share
1.51
9.66
Net current asset value per share
1.56
10.11
Tangible book value per share
0.9
6.85
Working capital per share
0.88
7.24
Book value per share
0.9
6.85
Nouvelles
Moderna's Shares Climb 5.3% as Investors Revisit Biotech Leaders
FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug
L’action d’Adagene s’envole après l’obtention du statut Fast Track de la FDA
Adagene stock soars after FDA grants Fast Track status for cancer therapy
La FDA accorde le statut accéléré au muzastotug d’Adagene pour le cancer colorectal
FDA grants fast track status to Adagene’s muzastotug for colorectal cancer
Adagene dose le premier patient dans un essai de phase 2 de muzastotug pour le CCR MSS
Adagene doses first patient in Phase 2 trial of muzastotug for MSS CRC
All You Need to Know About Adagene (ADAG) Rating Upgrade to Buy
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Les actions Adani en hausse après le rejet des allégations de Hindenburg par la SEBI
Adani shares rally as SEBI dismisses Hindenburg allegations